Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	121184
DOI	10.4251/wjgo.121184
Country	China

Category	Oncology
Manuscript Type	Clinical Trials Study
Article Title	Clinical application of a programmed death ligand-1 inhibitor combined with low-dose pulsed radiotherapy in recurrent metastatic hepatocellular carcinoma
Manuscript Source	Unsolicited Manuscript
All Author List	Xin-An Wan, Ming-Xing Fang, Le Yuan, Hang Zhang, Dan Wang and Zhao-Di Liu
Funding Agency and Grant Number	Funding Agency Grant Number Clinical Medical Research Transformation Project of Anhui Province of China No. 202204295107020064
Corresponding Author	Xin-An Wan, Chief Physician, MD, PhD, Department of Oncology, The Second People’s Hospital, Wuhu, No. 6 Duchun Road, Wuhu 241000, Anhui Province, China. 2263853630@qq.com
Key Words	Programmed death ligand-1 inhibitor; Pulsed radiotherapy; Hepatocellular carcinoma; Clinical application; T lymphocyte subsets
Core Tip	The combination of a programmed death ligand-1 inhibitor (atezolizumab) and low-dose pulsed radiation therapy has shown good efficacy and safety in some patients with recurrent metastatic hepatocellular carcinoma.
Citation	Wan XA, Fang MX, Yuan L, Zhang H, Wang D, Liu ZD. Clinical application of a programmed death ligand-1 inhibitor combined with low-dose pulsed radiotherapy in recurrent metastatic hepatocellular carcinoma. World J Gastrointest Oncol 2026; In press DOI: https://doi.org/10.4251/wjgo.121184
PDF	121184-in-press.pdf

Received	2026-03-18 06:34
Peer-Review Started	2026-03-18 06:34
First Decision by Editorial Office Director	2026-06-04 07:46
Return for Revision	2026-06-04 11:51
Revised	2026-06-16 13:55
Publication Fee Transferred	2026-06-23 13:54
Second Decision by Editor	2026-07-09 02:35
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-07-09 08:22
Articles in Press	2026-07-09 08:22
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1948-5204 (online)
Open Access	This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Copyright	©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com